Relypsa Loads $80M Series C to Fund Patiromer Phase III
Relypsa Inc. moved patiromer (RLY5016), its high-capacity nonabsorbed oral potassium binder, closer to the finish line in hyperkalemia by closing an $80 million Series C preferred stock financing to fund pivotal Phase III trials and submission of a new drug application (NDA).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST